ID: ALA4091222

Max Phase: Preclinical

Molecular Formula: C26H23N3O6

Molecular Weight: 473.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(OC)c2c(=O)[nH]c(-c3ccc(OCc4ccc(/C=C/C(=O)NO)cc4)cc3)nc2c1

Standard InChI:  InChI=1S/C26H23N3O6/c1-33-20-13-21-24(22(14-20)34-2)26(31)28-25(27-21)18-8-10-19(11-9-18)35-15-17-5-3-16(4-6-17)7-12-23(30)29-32/h3-14,32H,15H2,1-2H3,(H,29,30)(H,27,28,31)/b12-7+

Standard InChI Key:  CBKULAQYEDZKLZ-KPKJPENVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 473.49

Molecular Weight (Monoisotopic): 473.1587

AlogP: 3.70

#Rotatable Bonds: 8

Polar Surface Area: 122.77

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.31

CX Basic pKa: 3.10

CX LogP: 3.23

CX LogD: 3.23

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.20

Np Likeness Score: -0.31

References

1. Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L..  (2017)  Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.,  27  (17): [PMID:28765013] [10.1016/j.bmcl.2017.07.054]

2. Liu T,Wan Y,Xiao Y,Xia C,Duan G.  (2020)  Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.,  63  (17): [PMID:32320239] [10.1021/acs.jmedchem.0c00491]

Source

Source(1):

• Scientific Literature